Different maspin functions in the lung adenocarcinoma A549 and SPC-A1 cell lines

International Journal of Molecular Medicine

Volumn 36, Issue 5, 2015, Pages 1440-1448

  Zhou, Jun ^a   Hualong, Qin ^b   Zhou, Peng ^a   Guo, Feng ^a  

^a SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Adenocarcinoma; Cell growth; Lung cancer; Maspin; Migration

Indexed keywords

BETA1 INTEGRIN; GELATINASE A; GELATINASE B; K RAS PROTEIN; MASPIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SERINE PROTEINASE INHIBITOR; SERPIN-B5;

A549 CELL LINE; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPC A1 CELL LINE; ADENOCARCINOMA; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANTIGENS, CD29; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; POINT MUTATION; SERPINS;

EID: 84945422370     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2336     Document Type: Article

References (42)

1. Schiller JH, Gandara DR, Goss GD, and Vokes EE. Non small cell lung cancer: Then and now. J Clin Oncol. 31: 981 983, 2013.
2. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, and Sager R. Maspin, a serpin with tumor suppressing activity in human mammary epithelial cells. Science. 263: 526 529, 1994.
3. Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S, and Sesterhenn I. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clin Cancer Res. 8: 1172 1177, 2002.
4. Katakura H, Takenaka K, Nakagawa M, Sonobe M, Adachi M, Ito S, Wada H, and Tanaka F. Maspin gene expression is a significant prognostic factor in resected non small cell lung cancer (NSCLC). Maspin in NSCLC. Lung Cancer. 51: 323 328, 2006.
5. Lonardo F, Li X, Kaplun A, Soubani A, Sethi S, Gadgeel S, and Sheng S. The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. Curr Pharm Des. 16: 1877 1881, 2010.
6. Mohsin SK, Zhang M, Clark GM, and Craig Allred D. Maspin expression in invasive breast cancer: Association with other prognostic factors. J Pathol. 199: 432 435, 2003.
7. Joensuu KM, Leidenius MH, Andersson LC, and Heikkilä PS. High expression of maspin is associated with early tumor relapse in breast cancer. Hum Pathol. 40: 1143 1151, 2009.
8. Maass N, Hojo T, Ueding M, Lüttges J, Klöppel G, Jonat W, and Nagasaki K. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res. 7: 812 817, 2001.
9. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali Ellis Z, Arbour N, Seftor EA, and Hendrix MJ. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 8: 2924 2932, 2002.
10. Baek JY, Yeo HY, Chang HJ, Kim KH, Kim SY, Park JW, Park SC, Choi HS, Kim DY, and Oh JH. Serpin B5 is a CEA interacting biomarker for colorectal cancer. Int J Cancer. 134: 1595 1604, 2014.
11. Snoeren N, Emmink BL, Koerkamp MJ, van Hooff SR, Goos JA, van Houdt WJ, de Wit M, Prins AM, Piersma SR, Pham TV, et al. Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer. Br J Cancer. 109: 1636 1647, 2013.
12. Takagi Y, Matsuoka Y, Shiomi T, Nosaka K, Takeda C, Haruki T, Araki K, Taniguchi Y, Nakamura H, and Umekita Y. Cytoplasmic maspin expression is a predictor of poor prognosis in patients with lung adenocarcinoma measuring 3 cm. Histopathology. 66: 732 739, 2014.
13. Narayan M, and Twining S. Focus on molecules: Maspin. Exp Eye Res. 90: 2 3, 2010.
14. Teoh SS, Vieusseux J, Prakash M, Berkowicz S, Luu J, Bird CH, Law RH, Rosado C, Price JT, Whisstock JC, et al. Maspin is not required for embryonic development or tumour suppression. Nat Commun. 5: 3164, 2014.
15. Li X, Chen D, Yin S, Meng Y, Yang H, Landis Piwowar KR, Li Y, Sarkar FH, Reddy GP, Dou QP, et al. Maspin augments proteasome inhibitor induced apoptosis in prostate cancer cells. J Cell Physiol. 212: 298 306, 2007.
16. Tahmatzopoulos A, Sheng S, and Kyprianou N. Maspin sensitizes prostate cancer cells to doxazosin induced apoptosis. Oncogene. 24: 5375 5383, 2005.
17. Liu J, Yin S, Reddy N, Spencer C, and Sheng S. Bax mediates the apoptosis sensitizing effect of maspin. Cancer Res. 64: 1703 1711, 2004.
18. Latha K, Zhang W, Cella N, Shi HY, and Zhang M. Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Mol Cell Biol. 25: 1737 1748, 2005.
19. McKenzie S, Sakamoto S, and Kyprianou N. Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. Oncogene. 27: 7171 7179, 2008.
20. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, and Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA. 93: 11669 11674, 1996.
21. Cher ML, Biliran HR Jr, Bhagat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zachareas M, and Sheng S. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci USA. 100: 7847 7852, 2003.
22. Chen EI, and Yates JR. III: Maspin and tumor metastasis. IUBMB Life. 58: 25 29, 2006.
23. Ravenhill L, Wagstaff L, Edwards DR, Ellis V, and Bass R. G helix of maspin mediates effects on cell migration and adhesion. J Biol Chem. 285: 36285 36292, 2010.
24. Bircan A, Bircan S, Kapucuoglu N, Songur N, Ozturk O, and Akkaya A. Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinico-pathologic parameters. Pathol Oncol Res. 16: 553 561, 2010.
25. Berardi R, Santinelli A, Onofri A, Brunelli A, Pierantoni C, Pisa E, Pagliacci A, Stramazzotti D, Zuccatosta L, Mazzanti P, et al. Maspin expression is a favorable prognostic factor in non small cell lung cancer. Anal Quant Cytol Histol. 34: 72 78, 2012.
26. Frey A, Soubani AO, Adam AK, Sheng S, Pass HI, and Lonardo F. Nuclear, compared with combined nuclear and cyto-plasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF A levels and in Stage I, improved survival. Histopathology. 54: 590 597, 2009.
27. Kim S, Han J, Kim J, and Park C. Maspin expression is transac-Tivated by p63 and is critical for the modulation of lung cancer progression. Cancer Res. 64: 6900 6905, 2004.
28. Choy B, Findeis Hosey JJ, Li F, McMahon LA, Yang Q, and Xu H. High frequency of coexpression of maspin with p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of the lung. Int J Clin Exp Pathol. 6: 2542 2547, 2013.
29. Beltran AS, and Blancafort P. Reactivation of MASPIN in non small cell lung carcinoma (NSCLC) cells by artificial tran-scription factors (ATFs). Epigenetics. 6: 224 235, 2011.
30. Berardi R, Morgese F, Onofri A, Mazzanti P, Pistelli M, Ballatore Z, Savini A, De Lisa M, Caramanti M, Rinaldi S, et al. Role of maspin in cancer. Clin Transl Med. 2: 8, 2013.
31. Takanami I, Abiko T, and Koizumi S. Expression of maspin in non small cell lung cancer: Correlation with clinical features. Clin Lung Cancer. 9: 361 366, 2008.
32. Ali Labib R, Louka ML, Galal IH, and Tarek M. Evaluation of matrix metalloproteinase 2 in lung cancer. Proteomics Clin Appl. 8: 251 257, 2014.
33. Denk AE, Bettstetter M, Wild PJ, Hoek K, Bataille F, Dietmaier W, and Bosserhoff AK. Loss of maspin expression contributes to a more invasive potential in malignant melanoma. Pigment Cell Res. 20: 112 119, 2007.
34. Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, et al. Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer. 2: 1009 1022, 2011.
35. Yin S, Lockett J, Meng Y, Biliran H Jr, Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, et al. Maspin retards cell detachment via a novel interaction with the urokinase type plasminogen activator/urokinase type plasminogen activator receptor system. Cancer Res. 66: 4173 4181, 2006.
36. Endsley MP, Hu Y, Deng Y, He X, Warejcka DJ, Twining SS, Gonias SL, and Zhang M. Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facil-itates cell adhesion. J Biol Chem. 286: 24599 24607, 2011.
37. Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng Q, Lin HC, He XH, Li JJ, and Yao M. Integrative analyses identify osteo-pontin, LAMB3 and ITGB1 as critical pro metastatic genes for lung cancer. PLoS One. 8: e55714, 2013.
38. Jahangiri A, Aghi MK, and Carbonell WS: β1 integrin: Critical path to antiangiogenic therapy resistance and beyond. Cancer Res 74 3-7 2014.
39. Kanda R, Kawahara A, Watari K, Murakami Y, Sonoda K, Maeda M, Fujita H, Kage M, Uramoto H, Costa C, et al. Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt driven bypass signaling. Cancer Res. 73: 6243 6253, 2013.
40. Wojtalla A, and Arcaro A. Targeting phosphoinositide 3 kinase signalling in lung cancer. Crit Rev Oncol Hematol. 80: 278 290, 2011.
41. Nam E, and Park C. Maspin suppresses survival of lung cancer cells through modulation of Akt pathway. Cancer Res Treat. 42: 42 47, 2010.
42. Bentley C, Jurinka SS, Kljavin NM, Vartanian S, Ramani SR, Gonzalez LC, Yu K, Modrusan Z, Du P, Bourgon R, et al. A requirement for wild type Ras isoforms in mutant KRas driven signalling and transformation. Biochem J. 452: 313 320, 2013.